Table 3.
Treatment-related adverse events in the safety population (n = 31).
| Adverse event* | Grade 1–2 | Grade 3 | Grade 4 |
|---|---|---|---|
| Hypertension | 11 (35%) | 2 (6%) | 0 |
| Fatigue | 15 (48%) | 1 (3%) | 0 |
| Hand–foot syndrome | 10 (32%) | 1 (3%) | 0 |
| Anorexia | 12 (39%) | 0 | 0 |
| Oral mucositis | 6 (19%) | 1 (3%) | 0 |
| Diarrhea | 9 (29%) | 1 (3%) | 0 |
| Nausea | 8 (26%) | 0 | 0 |
| Vomiting | 2 (6%) | 1 (3%) | 0 |
| Headache | 5 (16%) | 0 | |
| Peripheral edema | 6 (19%) | 0 | 0 |
| Proteinuria | 4 (13%) | 0 | 0 |
| Increased AST | 3 (10%) | 0 | 0 |
| Increased ALT | 2 (6%) | 0 | 0 |
| Anemia | 3 (10%) | 0 | 0 |
| Thrombocytopenia | 1 (3%) | 0 | 0 |
| Neutropenia | 2 (6%) | 0 | 0 |
*
Adverse events related to treatment-related toxicity.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.